Table 2.
Pretransplant characteristics of included studies.
| Study | Sample Size (tPA vs. Non-tPA) | Donor Age (Years) (tPA vs. Non-tPA) | MELD Score (tPA vs. Non-tPA) | WIT Functional (Min) (tPA vs. Non-tPA) | CIT (Min) (tPA vs. Non-tPA) |
|---|---|---|---|---|---|
| Seal (2014) [23] | 85 vs. 33 | 36.3 ± 14.8 vs. 38.0 ± 14.9 (P = 0.99) |
20.1 ± 8.2 vs. 16.5 ± 10.8 (P = 0.38) |
21.1 ± 8.3 vs. 23.5 ± 7.6 (P = 0.16) |
306.0 ± 72.0 vs. 258.0 ± 60.0 (P = 0.004) |
| Eghtesad (Randomized) (2015) [33] | 11 vs. 12 | 61.8 ± 5.9 vs. 56.0 ± 11.0 (P = 0.13) |
22.0 ± 5.0 vs. 23.0 ± 5.0 (P = 0.63) |
21.0 ± 7.0 vs. 23.0 ± 4.0 (P = 0.40) |
389.0 ± 36.0 vs. 373.0 ± 76.0 (P = 0.53) |
| Eghtesad (Non-randomized) (2015) [33] | 35 vs. 22 | 56.0 ± 9.0 vs. 56.0 ± 11.0 (P = 0.99) |
22.0 ± 7.0 vs. 23.0 ± 6.0 (P = 0.58) |
25.0 ± 7.0 vs. 24.0 ± 7.0 (P = 0.63) |
387.0 ± 68.0 vs. 389.0 ± 107.0 (P = 0.93) |
| Kubal (2016) [21] | 30 vs. 61 | 31.5 ± 13.3 vs. 36.2 ± 14.7 (P = 0.14) |
23.2 ± 8.9 vs. 16.0 ± 5.8 (P < 0.001) |
19.0 ± 5.2 vs. 26.2 ± 7.2 (P = 0.01) |
288.0 ± 41.5 vs. 429.0 ± 138.5 (P < 0.001) |
| Bohorquez (2017) [24] | 100 vs. 38 | 37.8 ± 14.6 vs. 37.6 ± 14.6 (P = 0.95) |
20.7 ± 5.4 vs. 20.8 ± 5.7 (P = 0.92) |
20.4 ± 7.5 vs. 18.7 ± 10.6 (P = 0.3) |
304.0 ± 92.2 vs. 240.6 ± 45.7 (P < 0.001) |
Non-tPA, non-tissue plasminogen activator group (non-thrombolytic group); tPA, tissue plasminogen activator group (thrombolytic group); MELD, Model for End-Stage Liver Disease; WIT, Warm ischemia time; CIT, Cold ischemia time.